Study to Assess PK, Safety and Tolerability in Patients With DM and CKD

A Multi-Center Open-label Investigation to Assess the Pharmacokinetics, Safety and Tolerability of DM199 in Patients With Diabetes Mellitus and Chronic Kidney Disease

An open-label, phase IB, multi-center study evaluating DM199 in subjects with Type 1 Diabetes or Type 2 Diabetes and Stage 3 or 4 Chronic Kidney Disease. The primary objectives of this study are to evaluate safety, tolerability, and PK profile of DM199 in these subjects.

Study Overview

• Status: Completed
• Conditions: Diabetes; Chronic Kidney Disease; Chronic Kidney Disease, Stage 4 (Severe); Chronic Kidney Disease, Stage 3 (Moderate)
• Intervention / Treatment: Drug: DM199

Detailed Description

The study evaluates the safety, tolerability, and PK profile of DM199 in subjects with T1D or T2D and with Stage 3 or Stage 4 CKD. Additionally, this study evaluates urine concentrations of KLK1 pre and post dose.

Cohort 1: Subjects with T1D or T2D and Stage 3 CKD will be administered one of three DM199 doses: 3.0 ug/kg or 5.0 ug/kg or 8.0 ug/kg single SC dose. Cohort 2: Subjects with T1D or T2D and Stage 4 CKD will be administered a single 3.0 µg/kg single SC dose. Secondary and exploratory study objectives include collection and analysis of vital signs, biomarkers, eGFR, blood glucose, and ECG's.

• Study Type: Interventional
• Enrollment (Actual): 33
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Florida
    • Hialeah, Florida, United States, 33014
      • Clinical Pharmacology of Miami
    • Orlando, Florida, United States, 32803
      • Orlando Clinical Research Center Inc
  • Minnesota
    • Saint Paul, Minnesota, United States, 55114
      • Prism Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subject is willing and able to provide informed consent for study participation.
• Subject is ≥ 18 years of age.
• Subject has an established diagnosis of T1D or T2D as determined by medical evaluation at screen.
• Subjects A1c <9.8%
• Subject is clinically stable with respect to underlying renal impairment and diabetes, as assessed by the Investigator's medical evaluation.
• Subject has been diagnosed with Stage 3 CKD as defined by eGFR (MDRD) between 30 - <60 or Stage 4 as defined by eGFR <30 (not on dialysis) at screening.
• Subject has a body mass index (BMI) between 18 to 45 kg/m2 (inclusive).

Exclusion Criteria:

• Subject has positive drug test for drugs of abuse and/or positive alcohol breath test at screening and Day 0.
• Subject is unable or unwilling to comply with protocol requirements, including assessments, tests, and follow-up visits.
• Subject has a history of significant allergic diathesis such as urticaria, angioedema, or anaphylaxis.
• Subject has had any live vaccination ≤ 3 months prior to enrollment or will require vaccination during the study.
• Subject must not be taking an ACEi medication for 5 half-lives prior to study drug administration and for 5 days post study drug administration.
• Subject is unwilling or unable to limit smoking to ≤ 10 cigarettes per day (or other products that contain nicotine limited to < 200 mg of nicotine/day) during the study participation period.
• Subject has a current malignancy or active malignancy ≤ 3 years prior to enrollment except basal cell or squamous cell carcinoma of the skin or in situ cervical cancer that has undergone potentially curative therapy and ≥ six months have elapsed since the procedure.
• Subject has an active infection at the time of enrollment, and/or a history of clinically significant acute bacterial, viral, or fungal systemic infections that required systemic treatment in the last four weeks prior to enrollment.
• Subject has known medical history of alpha 1-antitrypsin deficiency (α1-antitrypsin deficiency).
• Subject has serological evidence of human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus (Anti-HCV) at screen.
• Subject is pregnant or nursing or is planning a pregnancy during the study period.
• Subject is male or female of childbearing potential, is participating in sexual activity that could lead to pregnancy and is unable or unwilling to practice medically effective contraception during the study.
• Subject has received any investigational drug or device within 14 days (or 5 half lives, whichever is longer) prior to study drug administration on Day 1
• Subject has renal artery stenosis as determine at screen with medical history.
• Subject has hypotension as defined by systolic blood pressure ≤ 90 and diastolic blood pressure ≤ 60 mmHg.
• Subject has Proteinuria: PCR>2000mg/gm (spot testing).
• Subject does not have adequate venous access for blood sampling.
• Subject has any other medical condition which, in the opinion of the Investigator, will make participation medically unsafe or interfere with the study results.
• Subject has any other clinically significant abnormalities in laboratory test results at screening that would, in the opinion of the Investigator, increase the subject's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data.

• Subject has any of the following conditions as determined by ECG or medical record:

  • Any significant arrhythmia or conduction abnormality, which, in the opinion of the Investigators and Medical Monitor, may interfere with the safety of the subject.
• Subject is taking Cimetidine, St. John's Wort, or any other herbal or probiotic supplement.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NON_RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 3.0 µg/kg SC, single dose; n=8, study group of T1D or T2D with stage 3 CKD. separate n=8 of study group with T1D or T2D with CKD stage 4).	Drug: DM199; Single SC dose
Experimental: 5.0 µg/kg SC, single dose; n=8, study group of T1D or T2D with stage 3 CKD.	Drug: DM199; Single SC dose
Experimental: 8.0 µg/kg SC, single dose; n=8, study group of T1D or T2D with stage 3 CKD.	Drug: DM199; Single SC dose

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety as assessed by incidence, severity, and causality of adverse events		11 days
Tolerability as assessed by incidence and severity of AEs		11 days
plasma measurements of DM199	as measured in the three different dosing groups; 3.0 ug/kg, 5.0 ug/kg, and 8.0 ug/kg.	11 days
DM199 urine concentrations of KLK1	urine KLK1 will be measured pre and post study drug administration.	11 days

Secondary Outcome Measures

Outcome Measure	Time Frame
C Reactive protein (CRP)	11 days
Matrix Metalloproteinase-9 (MMP-9)	11 days
Vascular Endothelial Growth Factor (VEGF)	11 days
Nitric Oxide (NO)	11 days
Serum creatinine	11 days
Cystatin C	11 days
neutrophil gelatinase-associated prostaglandin E2	11 days
Urine Kidney Injury Molecule-1 (Kim1)	11 days

Other Outcome Measures

Outcome Measure	Time Frame
serum creatinine	11 days
Blood glucose	11 days

Collaborators and Investigators

• Sponsor: DiaMedica Therapeutics Inc

Study record dates

Study Major Dates

• Study Start (Actual): February 12, 2019
• Primary Completion (Actual): July 21, 2019
• Study Completion (Actual): July 21, 2019

Study Registration Dates

• First Submitted: January 3, 2019
• First Submitted That Met QC Criteria: January 3, 2019
• First Posted (Actual): January 7, 2019

Study Record Updates

• Last Update Posted (Actual): September 13, 2021
• Last Update Submitted That Met QC Criteria: September 3, 2021
• Last Verified: July 1, 2019

More Information

Terms related to this study

• Keywords: Diabetes; Chronic Kidney Disease
• Additional Relevant MeSH Terms: Urologic Diseases; Renal Insufficiency; Kidney Diseases; Renal Insufficiency, Chronic
• Other Study ID Numbers: DM199-2018-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No